Expression of glucocorticoid and progesterone nuclear receptor genes in archival breast cancer tissue by Smith, Robert A et al.
Introduction
Breast cancer is the most common malignancy in women
in the Western world, with an incidence approaching 1/10
individuals in the USA in 1980 [1] and 1/11 in Australia in
1991. Several genetic and environmental risk factors have
already been identified, particularly for cancers with a
familial basis, including mutations within the BRCA1 and
BRCA2 genes [2]. Other risk factors include a maternal
relative with breast cancer, longer reproductive span,
obesity, reproductive history and previous breast cancers
[3]. Individual breast tumours are placed into one of three
histological grades. These grades are representative of
the degree of loss of differentiation and the acquisition of
various mutations [4]. Thus, higher grade tumour cells will
show fewer of the visual and functional characteristics of
the cell type from which they were derived. However,
cancer grade is only a rough guide to the state of any
given tumour, because the biology of cancer varies wildly
from one tumour to the next.
The nuclear receptor genes are an extremely large family
of genes that encode similar molecules, which bind to
various messenger molecules and are typically found at
or near the nuclear membrane [5]. The steroid nuclear
receptors are a subfamily of the nuclear receptors that
bind specifically to steroid hormones. Steroid receptors
consist of highly conserved DNA and ligand binding
domains, and a mutable hinge region connecting the two
[6]. Once the hormone for the specific receptor binds,
the receptor molecule moves across the nuclear mem-
brane and binds to a specific hormone response
element, which is a specialized sequence, on the tar-
geted genes [5]. Once bound to its target genes, the
receptor complex upregulates or downregulates the tran-
scription of those genes in a specific manner. Activated
steroid receptors affect many genes that are involved in
cellular metabolism and often affect the transcription of
other steroid receptors [7]. The overall action of any
steroid receptor pathway is rarely very simple, with many
ANOVA = analysis of variance; GR = glucocorticoid receptor; PgR = progesterone receptor; PCR = polymerase chain reaction.
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Abstract
Background: Previous studies in our laboratory have shown
associations of specific nuclear receptor gene variants with
sporadic breast cancer. In order to investigate these findings
further, we conducted the present study to determine whether
expression levels of the progesterone and glucocorticoid
nuclear receptor genes vary in different breast cancer grades.
Methods: RNA was extracted from paraffin-embedded archival
breast tumour tissue and converted into cDNA. Sample cDNA
underwent PCR using labelled primers to enable quantitation
of mRNA expression. Expression data were normalized against
the 18S ribosomal gene multiplex and analyzed using analysis
of variance.
Results: Analysis of variance indicated a variable level of
expression of both genes with regard to breast cancer grade
(P = 0.00033 for glucocorticoid receptor and P = 0.023 for
progesterone receptor).
Conclusion: Statistical analysis indicated that expression of
the progesterone nuclear receptor is elevated in late grade
breast cancer tissue.
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other signalling systems increasing, decreasing or modi-
fying their overall effect [7].
The two nuclear receptors investigated in the present
study, namely glucocorticoid receptor (GR) and proges-
terone receptor (PgR), are extremely important in breast
cancer physiology. PgR antagonizes many other nuclear
receptors, including the oestrogen receptor (oestrogen
being the most prevalent mitogenic factor in breast
cancers), whereas GR increases cellular differentiation
and has been known to induce apoptosis in certain cells
[6,8,9]. The level of expression of these nuclear receptors
in a cell gives an indication of how well the cell will
respond to stimulation by that hormone and can be
affected by many factors, including the activation of other
nuclear receptors. Expression of PgR is known to be
upregulated by an activated oestrogen receptor, whereas
expression of GR is downregulated by the same receptor.
Both the expression and alleles of the various nuclear
receptors have been implicated in cancer development
[5,7,10,11]. The research presented here investigates the
expression levels of PgR and GR in each of the three his-
tological grades of breast tissue, as compared with levels
of those nuclear receptors in normal breast tissue.
When assaying the expression of genes in cancer it is
important to remember that there is often a generalized
increase in mRNA production due to heightened cellular
metabolism, and certain genes that are often used to
gauge alterations in expression, such as the commonly
used  β-actin housekeeping gene, may also be affected
[12]. The gene used for the purpose in the present study,
namely the 18S ribosomal gene, is expressed at a basal
level in all cells and is necessary for protein production. It
is also used to help verify how reproducible the reverse
transcription PCR is.
Materials and methods
Samples
The sample population was comprised of 25 archived
breast tissue sections embedded in paraffin and fixed with
10% buffered formalin on slides, with haematoxylin and
eosin stained slides as a reference. All tumour samples
were infiltrating ductal carcinomas. There were six
samples from tumour grade 1, seven samples each from
grades 2 and 3, and five samples of benign breast tissue
as the control population. The average age of the individu-
als from whom the biopsies were obtained were 56.88,
59.18, 60.45 and 55.93 years for the control group and
grade 1, 2 and 3 groups, respectively. The archival breast
tissue samples were obtained through collaboration with
the Pathology Department of the Gold Coast Hospital,
with relevant ethical approvals. For consistency, the
cancer grade for each sample was determined by a single
pathologist from the Gold Coast Hospital’s Pathology
Department.
Expression assay
RNA was extracted from each slide by microdissection of
tumour tissue, followed by dissolution of the paraffin by
xylene and ethanol washes. Microdissection was per-
formed using a scalpel under an Olympus BX60 micro-
scope (Olympus Optical Co., Tokyo, Japan), using the
haematoxylin and eosin stained slides as a guide.
Microdissected tissue was then subjected to treatment
with TRIzol (Invitrogen, Carlsbad, CA, USA) to extract
RNA. Once the RNA was extracted, it was DNase treated
to remove any DNA contamination in the sample. Finally,
the samples were run through a Qiagen Rneasy mini-
column (Qiagen GmbH, Hilden, Germany) to purify the
RNA. The extracted RNA was then transcribed into cDNA,
using 0.1 µl AMV-RT, 0.2 µl buffer, 0.5 µl dNTPs and
0.5 µl of oligo dTs per 20 µl of RNA solution obtained. The
solution was then held at 42°C for 80 min to facilitate tran-
scription. Newly transcribed cDNA underwent PCR to
amplify portions of the cDNA that correspond to the
mRNA for the GR and PgR genes, with fluorescently
tagged primers. Primer details are provided in Table 1.
Fragments amplified were each approximately 100 base
pairs long, allowing cDNA derived from partially degraded
RNA to be fully utilized. Control for genomic DNA contami-
nation was provided by addition of a third primer to the
PCR, positioned in an intron adjacent to the amplified frag-
ment. If genomic contamination were present, then an addi-
tional, larger, fragment would appear. To control for PCR
efficiency, the GR and PgR genes were multiplexed with
the ribosomal 18S gene. The GR and PgR genes were
quantified using an ABI 310 Genetic Analyzer (Applied
Biosystems, Foster City, CA, USA), which measured the
amount of fluorescence given off by the tagged primers.
Statistical analysis
Expression data obtained for the GR and PgR genes were
normalized using the expression data obtained for the 18S
gene, which had been multiplexed with each tumour and
control sample. As mentioned above, this controls for
PCR efficiency by normalizing the data. The normalized
data were then analyzed using one-way analysis of vari-
ance (ANOVA) to determine whether there was a signifi-
cant difference between tumour grades. However, to
protect against spurious results caused by the effect of
outliers, the nonparametric Kruskal–Wallis test for K inde-
pendent groups was also employed to confirm differences
between the tumour grade groups. Appropriate post hoc
tests were subsequently performed to elucidate any differ-
ences found. P < 0.05 was considered statistically signifi-
cant. The software package SPSS version 10.1 was
employed for all statistical analyses (SPSS Inc., Chicago,
IL, USA).
Results
Expression levels for GR and PgR were determined for all
archival tissue samples, and the normalized data are sum-R11
marised in Table 2. Statistical values are summarized in
Table 3, which shows that the expression ratios for
grade 3 tumours were elevated for both GR and PgR.
One-way ANOVA indicated that the differences between
tumour grades were significant (P = 0.00033 and
P = 0.023 for GR and PgR, respectively). The notable
extreme ratio values seen for both genes in the grade 3
tumour group (Table 2) prompted us to analyze the data
using the nonparametric Kruskal–Wallis test, which is
robust against the effect of outliers. The results of that
analysis also revealed a significant difference between
tumour groups for the GR and PgR genes (P = 0.048 and
P = 0.001, respectively).
In order to elucidate the source of the significant differ-
ences found in the initial analyses, post hoc testing was
performed. Because parametric post hoc tests are also
susceptible to severe violation of assumptions, a nonpara-
metric method involving multiple contrasts of rank sums
was conducted [13]. The results of the post hoc analysis
for the PgR confirmed that expression ratios in grade 3
tumour tissues were significantly higher than in grade 1 or
control tissue (P < 0.05). However, no significant differ-
ence was observed between grade 3 and grade 2 ratios
for the PgR gene. For the GR gene, post hoc comparisons
revealed no significant differences between any test
groups at the 0.05 level. This is possibly due to insufficient
power to detect the tumour grade effect seen here with
the sample size studied.
Discussion
The GR and PgR genes are members of the steroid
receptor subfamily of the nuclear receptors. The present
study investigated the expression of these genes in differ-
ent grades of breast cancer tissue. Results indicated that
there is significant statistical evidence of a relationship
between cancer grade and expression of GR and PgR
within the tested population. Specifically, post hoc tests
indicated that expression of the PgR gene increased in
late-stage breast cancer. It is possible that the PgR may
be being expressed in response to constant stimulation of
oestrogen-mediated pathways, because oestrogen recep-
tor stimulation is known to upregulate PgR expression
[14]. This explanation is unlikely for GR because it is
known to be downregulated by oestrogen receptor stimu-
lation [15], although it is unknown whether the loss of the
actual oestrogen receptor protein, as occurs in many
advanced cancers, would affect GR expression.
Because both GR and PgR are oestrogen antagonists
and antimitogenic agents in breast tissue, a high level of
expression of these genes in an advanced cancer appears
unusual. It may be that the tumour cell expresses these
genes as a tumour repressing mechanism, but that
another pathway in the cell is preventing translation of GR
and PgR mRNA, maintaining a cancerous state. It is also
possible that the GR and PgR genes are expressed as
Available online http://breast-cancer-research.com/content/5/1/R9
Table 1
Primer compositions for PCRs
Primer name Sequence (5′–3′)
GREX2-F1* GAGTACCTCTGGAGGACAGA
GREX2-R1 GCTTCTGATCCTGCTGTTGA
GREX2-R2 ATGTCCATTCTTAAGAAACAGGA
PREX4-F1* ATTGATGACCAGATAACTCTCCAT
PREX4-R1 CTGACGTGTTTGTAGGATCTC
PREX4-R2 GTAGTTAATTTACTGCATAGAGTG
18S-A† CTTAGAGGGACAAGTCGCG
18S-B GGACATCTAAGGGCATCACA
*Primer labelled with TET at 5′; †Primer labelled with HEX at 5′.
Table 2
Normalized expression data for glucocorticoid receptor and
progesterone receptor
Ratio
Tumour grade Sample GR PgR
1 1.1 0.157663 1.704581
1.2 0.286386 0.704097
1.3 0.210192 0.677007
1.4 0.297708 0.394194
1.5 0.412451 0.851367
1.6 0.21291 1.145151
2 2.1 0.213596 1.334635
2.2 0.171545 1.071429
2.3 0.305254 0.836883
2.4 0.283253 1.840524
2.5 0.329755 0.811868
2.6 0.187681 0.73115
2.7 0.160085 0.729422
3 3.1 1.413502 1.577562
3.2 1.013641 6.979079
3.3 0.879098 9.649718
3.4 1.978049 3.449206
3.5 1.021454 34.26531
3.6 0.602367 15.52174
3.7 0.146503 1.246472
Control C1 0.377536 0.441603
C2 0.285381 0.541582
C3 0.063817 0.815374
C4 0.2168 0.64433
C5 0.166092 0.383313
GR, glucocorticoid receptor; PgR, progesterone receptor.alternate isoforms of the receptors, which cannot be dis-
tinguished by the methods employed in the present study.
Alternate isoforms are known for both receptors: the alter-
native GR, namely GRβ, acts as a repressor of antioestro-
genic GR (GRα) activity [6]; and with the PgR alternative
(i.e. PgRβ) acts as a general gene activator, in contrast to
the standard PgRα isoform, which is generally a transcrip-
tion inhibitor [16]. Both of these roles appear more recog-
nizable in advanced cancers, which are often resistant to
hormonal treatments. Further studies in this area should
ideally use larger sample sizes but should also attempt to
investigate other nuclear receptors, as well as attempting
to distinguish different receptor isoforms and identify the
presence of translated receptor proteins.
Conclusion
The results of this preliminary study indicate that the
expression of the GR and PgR genes is significantly
related to cancer grade, especially for PgR, increasing in
late stage breast cancers. The overall significance of these
results for therapeutic work is not fully clear, because the
possibility of alternate isoform expression or prevention of
receptor translation will have a large impact on the physiol-
ogy of the cancer cell, and therefore on the appropriate
treatment strategies to utilize this information.
Acknowledgements
This research was kindly supported by the Wesley Research Institute,
Brisbane, Queensland, Australia.
References
1. King M-C, Roswell S, Love SM: Inherited breast and ovarian
cancer: what are the risks? What are the choices? JAMA
1993, 269:1975-1980.
2. Zheng L, Li S, Boyer TG, Lee WH: Lessons learned from
BRCA1 and BRCA2. Oncogene 2000, 19:6159-6175.
3. Curran JE, Weinstein SR, Griffiths LR: Polymorphisms of glu-
tathione S-transferase genes (GSTM1, GSTP1 and GSTT1)
and breast cancer susceptibility. Cancer Lett 2000, 153:113-
120.
4. Berardo D, Allred DC, O’Connell P: Breast cancer. In: Principles
of molecular medicine. Totowa, NJ: Humana Press; 1998:625-
632.
5. Fryer CJ, Kinyamu HK, Rogatsky I, Garabedian MJ, Archer TK:
Selective activation of the glucocorticoid receptor by steroid
antagonists in human breast cancer and osteosarcoma cells.
J Biol Chem 2000, 275:17771-17777.
6. Keightley M-C: Steroid receptor isoforms: exception or rule?
Mol Cell Endocrinol 1998, 137:1-5.
7. Dickson RB, Lippman ME. Control of human breast cancer by
estrogen, growth factors, and oncogenes. Cancer Treat Res
1988, 40:119-165.
8. Lee Y-N, Lee H-Y, Lee YM, Chung H-Y, Kim S-I, Lee S-K, Park
BC, Kim K-W: Involvement of glucocorticoid receptor in the
induction of differentiation by ginsenosides in F9 teratocarci-
noma cells. J Steroid Biochem Mol Biol 1998, 67:105-111.
9. Hulkko SM and Zilliacus J: Functional interaction between the
pro-apoptotic DAP3 and the glucocorticoid receptor. Biochem
Biophys Res Commun 2002, 295:749-755.
10. Curran JE, Vaughan T, Lea RA, Weinstein SR, Morrison NA, Grif-
fiths LR: Association of a vitamin D receptor polymorphism
with sporadic breast cancer development. Int J Cancer 1999,
83:723-726.
11. Karck U, Kommoss F: Does tamoxifen change oestrogen and
progesterone receptor expression in the endometrium and
breast? Eur J Cancer 2000, 36:S39-S46.
12. Selvey S, Thompson EW, Matthaei K, Lea RA, Irving MG and Grif-
fiths LR. Β Β-Actin: an unsuitable internal control for RT-PCR.
Mol Cell Probes 2001, 15:307-311.
13. Dunn OJ. Multiple contrasts using rank sums. Technometrics
1964, 6:241-252.
14. Fazzari A, Catalano MG, Comba A, Becchis M, Raineri M, Frairia
R, Fortunati N: The control of progesterone receptor expres-
sion in MCF-7 breast cancer cells: effects of estradiol and sex
hormone-binding globulin (SHBG). Mol Cell Endocrinol 2001,
172:31-36.
15. Krishnan AV, Swami S, Feldman D: Estradiol inhibits glucocorti-
coid receptor expression and induces glucocorticoid resis-
tance in MCF-7 human breast cancer cells. J Steroid Biochem
Mol Biol 2001, 77:29-37.
16. Pieber D, Allport VC, Bennett PR: Progesterone receptor
isoform A inhibits isoform B-mediated transactivation in
human amnion. Eur J Pharmacol 2001, 427:7-11.
Correspondence
Professor Lyn Griffiths, Genomics Research Centre and Wesley Research
Institute, School of Health Science, Griffith University Gold Coast, PMB 50
Gold Coast Mail Centre QLD 9726, Australia. Phone: +61 7 5552 8664;
fax: +61 7 5552 8908; e-mail: L.Griffiths@mailbox.gu.edu.au
Breast Cancer Research    Vol 5 No 1 Smith et al.
R12
Table 3
Summary of normalized expression data for glucocorticoid receptor and progesterone receptor genes
Ratios
GR PgR
Tumour grade Mean Mean rank Mean Mean rank
1 0.263 11.33 0.913 10.33
2 0.236 10.29 1.051 12.86
3 1.007 19.57 10.384 21.29
Control 0.222 9.600 0.565 4.800
Statistic* F = 9.644 χ2 = 7.908 F =3.900  χ2 = 15.869
P value 0.00033 0.048 0.023 0.001
*F statistics for group means were calculated using analysis of variance and χ2 statistics for mean ranks were calculated using the Kruskal–Wallis
test. GR, glucocorticoid receptor; PgR, progesterone receptor.